United Kingdom-based ViiV Healthcare has reported that two phase three trials assessing the two-drug regimen (2DR) of dolutegravir (Tivicay) and lamivudine (Epivir) in treatment naive HIV-1 infected adults demonstrated the ability to control HIV.
It was reported on Friday that the trials, named GEMINI-1 and GEMINI-2, evaluated the 2DR against a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors in HIV-1 patients with baseline viral loads under 500,000 copies per ml. The nucleoside reverse transcriptase inhibitors used in the trials were tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Non-inferiority based on plasma HIV-1 RNA
genedrive secures initial overseas orders for Genedrive MT-RNR1 ID kit
Kromek collaborates on next-gen CT detector technology
Gilead Sciences initiates Phase 2 trial in Europe to evaluate lenacapavir for HIV prevention
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Celanese to supply VitalDose drug delivery platform for Population Council's MPT Intravaginal Ring
Henry Schein introduces equipment repair subscription - Henry Schein Thrive Service Plus
Seres Therapeutics provides business updates and reports Q2 2023 financial results